|
Commitments and Contingencies (Details) (USD $)
|
12 Months Ended |
|---|---|
|
Dec. 31, 2012
|
|
|
Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | $ 750,000 |
|
Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 750,000 |
|
Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 1,500,000 |
|
Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 1,750,000 |
|
Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 1,500,000 |
|
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 1,500,000 |
|
MSKCC [Member] | New Drug Application [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | 750,000 |
|
MSKCC [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]
|
|
| Summary of milestone payment | |
| Milestones payments | $ 1,750,000 |